ASH 2017 | Novel agent filanesib combination therapy for R/R multiple myeloma

Enrique Ocio

Filanesib is a novel agent that has previously shown clinical activity in pretreated multiple myeloma (MM) patients. In this interview, Enrique Ocio, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, gives us an overview of the Phase Ib/II trial (NCT02384083), which evaluated filanesib in combination with pomalidomide and dexamethasone in relapsed/refractory MM. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Share this video